Plasma biomarkers for Alzheimer’s Disease in relation to neuropathology and cognitive change

[1]  Nick C Fox,et al.  Population-based blood screening for preclinical Alzheimer’s disease in a British birth cohort at age 70 , 2020, Brain : a journal of neurology.

[2]  O. Hansson,et al.  Comparing the clinical utility and diagnostic performance of cerebrospinal fluid P‐tau181, P‐tau217 and P‐tau231 assays , 2021, Alzheimer's & Dementia.

[3]  C. Jack,et al.  Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. , 2021, JAMA neurology.

[4]  K. Blennow,et al.  Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers , 2021, EMBO molecular medicine.

[5]  C. Jack,et al.  Developing the ATX(N) classification for use across the Alzheimer disease continuum , 2021, Nature Reviews Neurology.

[6]  W. M. van der Flier,et al.  Diagnostic Value of the CSF α-Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies , 2021, Neurology.

[7]  O. Hansson,et al.  Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations , 2021, Nature Communications.

[8]  P. Svenningsson,et al.  A multicentre validation study of the diagnostic value of plasma neurofilament light , 2021, Nature Communications.

[9]  R. Liguori,et al.  RT‐QuIC Detection of Pathological α‐Synuclein in Skin Punches of Patients with Lewy Body Disease , 2021, Movement disorders : official journal of the Movement Disorder Society.

[10]  D. Holtzman,et al.  A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis , 2021, Molecular Neurodegeneration.

[11]  M. Bondi,et al.  Elevated plasma neurofilament light predicts a faster rate of cognitive decline over 5 years in participants with objectively‐defined subtle cognitive decline and MCI , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[12]  K. Blennow,et al.  Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology , 2021, Acta Neuropathologica.

[13]  K. Blennow,et al.  Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures , 2021, Nature Medicine.

[14]  K. Blennow,et al.  Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected , 2020, EMBO molecular medicine.

[15]  Patrick J. Lao,et al.  Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study , 2020, medRxiv.

[16]  M. Albert,et al.  Sequence of Alzheimer disease biomarker changes in cognitively normal adults , 2020, Neurology.

[17]  W. Klunk,et al.  Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer’s disease , 2020, Acta Neuropathologica.

[18]  W. Jagust,et al.  Association of CSF Aβ, amyloid PET, and cognition in cognitively unimpaired elderly adults , 2020, Neurology.

[19]  K. Blennow,et al.  Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. , 2020, JAMA.

[20]  K. Blennow,et al.  Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline , 2020, Acta Neuropathologica.

[21]  F. Schmitt,et al.  Prevalence and Clinical Phenotype of Quadruple Misfolded Proteins in Older Adults. , 2020, JAMA neurology.

[22]  K. Blennow,et al.  Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts , 2020, The Lancet Neurology.

[23]  OUP accepted manuscript , 2020, Brain.

[24]  P. Worley,et al.  Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease , 2019, Alzheimer's & dementia.

[25]  C. Brayne,et al.  Epidemiological pathology of Aβ deposition in the ageing brain in CFAS: addition of multiple Aβ-derived measures does not improve dementia assessment using logistic regression and machine learning approaches , 2019, Acta Neuropathologica Communications.

[26]  James G. Bollinger,et al.  High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis , 2019, Neurology.

[27]  C. Jack,et al.  Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report , 2019, Brain : a journal of neurology.

[28]  D. Salmon,et al.  Trajectories of cognitive decline differ in hippocampal sclerosis and Alzheimer's disease , 2019, Neurobiology of Aging.

[29]  Dag Aarsland,et al.  Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration , 2019, Acta neuropathologica communications.

[30]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[31]  D. Galasko,et al.  Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC , 2018, Acta Neuropathologica Communications.

[32]  C. Rowe,et al.  High performance plasma amyloid-β biomarkers for Alzheimer’s disease , 2018, Nature.

[33]  S. Leurgans,et al.  Varied effects of age-related neuropathologies on the trajectory of late life cognitive decline , 2017, Brain : a journal of neurology.

[34]  S. Swetter.  a population based , 2017 .

[35]  O. Hansson,et al.  Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography , 2016, Brain : a journal of neurology.

[36]  Charles Duyckaerts,et al.  National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.

[37]  T. Montine,et al.  RESEARCH ARTICLE: Empiric Refinement of the Pathologic Assessment of Lewy‐Related Pathology in the Dementia Patient , 2008, Brain pathology.

[38]  H. Braak,et al.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry , 2006, Acta Neuropathologica.

[39]  Dennis W. Dickson,et al.  Alzheimer Disease With Amygdala Lewy Bodies: A Distinct Form of &agr;-Synucleinopathy , 2006, Journal of neuropathology and experimental neurology.

[40]  H. Braak,et al.  Sequence of Aβ‐Protein Deposition in the Human Medial Temporal Lobe , 2000 .

[41]  J. Trojanowski,et al.  Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.

[42]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.